Education
About Us
Working with TipRanks
Follow Us
Alaunos Therapeutics (TCRT)
NASDAQ:TCRT
TCRT Stock Chart & Stats
$3.56
-$0.04(-2.13%)
At close: 4:00 PM EST
$3.56
-$0.04(-2.13%)
Day’s Range― - ―
52-Week Range$1.31 - $6.20
Previous CloseN/A
Volume6.23K
Average Volume (3M)860.99K
Market Cap
$7.95M
Enterprise Value$3.47M
Total Cash (Recent Filing)$1.94M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.92
Shares Outstanding2,231,829
10 Day Avg. Volume2,529,145
30 Day Avg. Volume860,987
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.48
Price to Sales (P/S)305.84
P/FCF Ratio-0.62
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue578.84
Enterprise Value/Gross Profit-19.40
Enterprise Value/Ebitda-0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Alaunos Therapeutics News
TCRT FAQ
What was Alaunos Therapeutics’s price range in the past 12 months?
Alaunos Therapeutics lowest stock price was $1.31 and its highest was $6.20 in the past 12 months.
What is Alaunos Therapeutics’s market cap?
Alaunos Therapeutics’s market cap is $7.95M.
When is Alaunos Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alaunos Therapeutics’s earnings last quarter?
Alaunos Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.705 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.705.
Is Alaunos Therapeutics overvalued?
According to Wall Street analysts Alaunos Therapeutics’s price is currently Overvalued.
Does Alaunos Therapeutics pay dividends?
Alaunos Therapeutics does not currently pay dividends.
What is Alaunos Therapeutics’s EPS estimate?
Alaunos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alaunos Therapeutics have?
Alaunos Therapeutics has 2,231,829 shares outstanding.
What happened to Alaunos Therapeutics’s price movement after its last earnings report?
Alaunos Therapeutics reported an EPS of -$0.705 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.481%.
Which hedge fund is a major shareholder of Alaunos Therapeutics?
Currently, no hedge funds are holding shares in TCRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alaunos Therapeutics
Alaunos Therapeutics (TCRT) is a biotechnology company focused on the development and commercialization of innovative, cell-based cancer immunotherapies. Operating within the healthcare and biotechnology sectors, the company is committed to advancing its proprietary T-cell receptor (TCR) therapy platform. This platform is designed to harness the power of the body's immune system to target and destroy cancer cells, offering potential treatments for a variety of solid tumor cancers.
Technical Analysis
AIM ImmunoTech
―
Cyclerion Therapeutics
―
NLS Pharmaceutics
―
GRI Bio
―
Calidi Biotherapeutics
―
Ownership Overview
13.90% Insiders
2.39% Mutual Funds
<0.01% Other Institutional Investors
83.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---